Pharmacological Interventions in COVID-19 Treatment

The global effort to treat COVID-19 has evolved from emergency use of broad-spectrum antivirals to targeted therapies that modulate viral entry, replication and the host inflammatory response. Direct-acting agents include nucleoside analogues that inhibit the viral RNA polymerase and small-molecule protease inhibitors designed to block essential viral enzymes. Monoclonal antibodies and engineered protein therapeutics have been deployed to neutralise viral particles and to target pathogenic host cytokines. Repurposed drugs have proven a rich source of candidates: host-directed therapies such as kinase inhibitors and functional inhibitors of acid sphingomyelinase (FIASMAs) interfere with cellular pathways exploited by SARS-CoV-2, while selected antidepressants exhibit both antiviral and anti-inflammatory properties. Immunomodulators, notably corticosteroids and interleukin-6 receptor antagonists, have reduced mortality among patients with severe respiratory distress. More recently, small-molecule inhibitors of the Raf/MEK/ERK signalling cascade have shown promise in limiting both viral replication and hyperinflammation. These pharmacological advances reflect an integrated approach that combines viral inhibition with careful management of host immune responses. The global significance of this work is underscored by the need for treatments suited to diverse healthcare settings, including resource-limited regions where access to advanced biologics may be constrained. Taken together, these developments illustrate a shift towards combination regimens, guided by an understanding of viral lifecycles, host-pathogen interfaces and the mechanisms underlying COVID-19–associated tissue damage.

Research from Nature Portfolio

Recent studies have demonstrated that the selective serotonin reuptake inhibitor fluoxetine possesses direct antiviral activity against SARS-CoV-2 in human lung tissue. In precision-cut lung slices, therapeutic concentrations of fluoxetine significantly reduced viral infectivity and protein expression without cytotoxic effects. Both stereoisomers of fluoxetine exhibited comparable antiviral potency, suggesting a mechanism distinct from serotonin reuptake inhibition. This work highlights the potential for repurposing widely available antidepressants as adjunctive therapies, capable of localised antiviral action in the respiratory tract and modulation of cytokine release, thereby addressing both viral load and host inflammatory responses.

Pharmacological Interventions in COVID-19 Treatment publication trend

The graph below shows the total number of articles in pharmacological interventions in covid-19 treatment across all publications each year (not limited to Nature Index journals).

Technical terms

FIASMA: Functional inhibitor of acid sphingomyelinase, a compound that prevents ceramide formation and disrupts viral entry platforms.

Cytokine storm: Excessive release of pro-inflammatory cytokines leading to tissue damage and organ dysfunction in severe infections.

MEK1/2 inhibitor: A drug that blocks mitogen-activated protein kinase kinases 1 and 2, interrupting a signalling cascade essential for viral replication and inflammatory mediator production.

Sigma-1 receptor: An endoplasmic reticulum chaperone that modulates cellular stress responses and viral replication, and can be targeted by certain antidepressants for therapeutic effect.

References

1. Targeting the endolysosomal host-SARS-CoV-2 interface by clinically licensed functional inhibitors of acid sphingomyelinase (FIASMA) including the antidepressant fluoxetine. Emerging Microbes & Infections (2020).
2. The serotonin reuptake inhibitor Fluoxetine inhibits SARS-CoV-2 in human lung tissue. Scientific Reports (2021).
3. The acid sphingomyelinase/ceramide system in COVID-19. Molecular Psychiatry (2021).
4. Fluvoxamine for Outpatient Management of COVID-19 to Prevent Hospitalization. JAMA Network Open (2022).
5. The MEK1/2-inhibitor ATR-002 efficiently blocks SARS-CoV-2 propagation and alleviates pro-inflammatory cytokine/chemokine responses. Cellular and Molecular Life Sciences (2022).